Business Context and Reporting Period
This Form 8-K was filed by Second Sight Medical Products, Inc. (not Vivani Medical, Inc.) on December 14, 2018, reporting events occurring on December 12, 2018. The filing details a private placement of equity securities.
Key Financial Metrics
- Gross Proceeds: Approximately $3 million.
- Shares Issued: 3,275,100 shares of common stock.
- Price Per Share: $0.916 (last reported sale price on the effective date).
- Transaction Costs: No placement agent or investment banking fees were incurred.
- Ownership Impact: Post-transaction, entities beneficially owned by Gregg Williams (Chairman) hold approximately 47.49% of outstanding common shares and 51.79% including warrant-acquirable shares.
Note: This filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change is the increase in outstanding common stock and the shift in ownership concentration following the private placement. The transaction was executed under Rule 506 of Regulation D and Section 4(a)(2) of the Securities Act of 1933, exempting the shares from registration.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond standard securities law disclosures. The shares issued are restricted and may not be offered or sold in the United States absent registration or an applicable exemption.
Investor Verification Checklist
- Verify the exact post-transaction ownership percentage of Gregg Williams and related entities.
- Confirm the use of the $3 million in gross proceeds as disclosed in subsequent filings or press releases.
- Review the attached Securities Purchase Agreement (Exhibit 10.1) for any covenants or restrictions not summarized in the 8-K.
- Check for any dilution impact on existing shareholders given the issuance of 3,275,100 new shares.